As a trusted obstetrician/gynecologist, you understand the importance of accurate and reliable prenatal screening. That's why we are proud to introduce our complete solution, combining the power of Thermo Scientific B·R·A·H·M·S Biomarkers, Thermo Scientific B·R·A·H·M·S KRYPTOR Instruments, and Thermo Scientific B·R·A·H·M·S Fast Screen Software. With over 25 years of expertise in the field, we are committed to providing you with the tools and support you need to make confident clinical decisions.
Complete biomarker portfolio for pre-eclampsia management:
Our solution provides a complete biomarker portfolio for pre-eclampsia management. With a wide range of assays tailored to specific needs, you can confidently assess risk and make informed clinical decisions.
All the intended uses covered by our assays have been clinically validated, ensuring the highest clinical performance and are fully compliant with the IVDR regulation.
T1 | T2 (from week 20) | T3 | Cut-off | |
Screening | PIGF PAPP-A |
PIGF sFlt-1 |
PIGF sFlt-1 |
It is the responsibility of the user to choose the cut-off which will apply for further procedures |
Aid for diagnosis | sFlt-1/PGIF | sFlt-1/PGIF | 85 | |
Short-term prediction | sFlt-1/PGIF | sFlt-1/PGIF | 66 |
In the US, with B·R·A·H·M·S sFlt-1/PlGF KRYPTOR Test System, we are proud to offer the first FDA approved assays to stratify pregnant women with pre-eclampsia with severe features.
*As defined by the American College of Obstetricians and Gynecologists (ACOG) guidelines.
**Preeclampsia, chronic hypertension with or without superimposed preeclampsia, or gestational hypertension.
Reliable results due to good precision and low interference:
We understand the importance of accurate results in prenatal screening. Our KRYPTOR instruments utilize advanced technology to deliver reliable and precise measurements, minimizing interference and ensuring the highest level of confidence in your patients' results. All B·R·A·H·M·S KRYPTOR Prenatal Screening Assays fulfill the strict quality requirements of the Fetal Medicine Foundation (FMF).
Confidence in clinical decisions:
Thermo Fisher Scientific boasts over 25 years of market presence and expertise in prenatal screening concepts, making it the preferred partner of hundreds of screening laboratories worldwide. More than 170 studies have been performed on B·R·A·H·M·S KRYPTOR Analyzers to establish and improve prenatal screening.
With our complete solution, you can have full confidence in your clinical decisions. Our validated assays, state-of-the-art instruments, and intuitive software work seamlessly together, providing you with accurate data and actionable insights to guide your patient's care.
Expertise:
Benefit from our 25 years of expertise in the field of prenatal screening. We have a deep understanding of the complexities involved and have continuously evolved our solutions to meet changing needs. Partner with us to leverage our experience and stay at the forefront of prenatal care.
Educational support:
We believe in equipping clinicians with the knowledge and resources to excel in their practice. Our educational support includes literature reviews, webinars, and access to a network of experts. We are committed to your professional success.
Thermo Fisher Scientific products are distributed globally and their uses, applications, indications, claims and availability of products in each country depend on local regulatory marketing authorization status, please consult the Instructions For Use (IFU) available in your country.
© 2024 Thermo Fisher Scientific Inc. All rights reserved. All trademarks are the property of Thermo Fisher Scientific and its subsidiaries unless otherwise specified. B·R·A·H·M·S is a registered trademark of B·R·A·H·M·S GmbH.
KRYPTOR and TRACE are trademarks of Cisbio Bioassays, licensed for use by B·R·A·H·M·S GmbH, a part of Thermo Fisher Scientific. Nobel Prize is a registered trademark of the Nobel Foundation.